Literature DB >> 9384457

Economic evaluation of pharmaceuticals: what are reasonable standards for clinical evidence--the Australian experience.

S Hill1, D Henry, B Pekarsky, A Mitchell.   

Abstract

Mesh：

Substances：

Year:  1997        PMID： 9384457      PMCID： PMC2042870          DOI： 10.1046/j.1365-2125.1997.t01-1-00597.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  4 in total

1.  The need for pharmacoeconomic evaluations in the NHS.

Authors:  J P Griffin
Journal:  Pharmacoeconomics       Date:  1998-09       Impact factor: 4.981

2.  Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: olmesartan medoxomil compared with losartan, valsartan, and irbesartan.

Authors:  W Robert Simons
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

3.  Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy.

Authors:  Thomas Faunce; Evan Doran; David Henry; Peter Drahos; Andrew Searles; Brita Pekarsky; Warwick Neville
Journal:  Global Health       Date:  2005-10-06       Impact factor: 4.185

4.  Drug policy down under: Australia's pharmaceutical benefits scheme.

Authors:  Stephen J Duckett
Journal:  Health Care Financ Rev       Date:  2004
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.